Literature DB >> 8778194

Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma.

O Noguchi1, N Enomoto, T Ikeda, F Kobayashi, F Marumo, C Sato.   

Abstract

BACKGROUND/AIMS: The roles of c-met proto-oncogene and hepatocyte growth factor in human livers have not been shown.
METHODS: Gene expressions of both c-met and hepatocyte growth factor were quantified in livers with chronic active hepatitis and in cirrhotic livers with hepatocellular carcinoma as well as in normal controls, using competitive reverse transcription polymerase chain reaction.
RESULTS: C-met expression was significantly increased in chronic active hepatitis compared with control livers, and c-met expression in chronic active hepatitis correlated with serum alanine aminotransferase levels. Hepatocyte growth factor expression was increased in some patients with chronic active hepatitis compared with controls, and there was a significant correlation between c-met expression and hepatocyte growth factor expression. On the other hand, in hepatocellular carcinoma tissues, c-met expression was increased in some cases, while that in the surrounding non-carcinomatous tissues was similar to normal controls. Hepatocyte growth factor expression was not detected in the hepatocellular carcinoma tissues and was low in the surrounding non-carcinomatous tissues.
CONCLUSIONS: These findings suggest that hepatocyte growth factor may be involved in the regeneration of hepatocytes via paracrine mechanism in chronic active hepatitis, while in regulation of c-met expression in hepatocellular carcinoma tissues may be independent of hepatocyte growth factor stimulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8778194     DOI: 10.1016/s0168-8278(96)80006-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

1.  Gene expression of hepatocyte growth factor and its receptor in HCC and nontumorous liver tissues.

Authors:  Yun-Quan Luo; Meng-Chao Wu; Wen-Ming Cong
Journal:  World J Gastroenterol       Date:  1999-04       Impact factor: 5.742

Review 2.  Targeting the HGF/c-MET pathway in hepatocellular carcinoma.

Authors:  Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

3.  Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.

Authors:  Kyung Hee Lee; Eun Young Choi; Myung Soo Hyun; Byung Ik Jang; Tae Nyeun Kim; Heon Ju Lee; Jong Yuel Eun; Hong Gin Kim; Sung Soo Yoon; Dong Sik Lee; Jung Hye Kim; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2007-11-09       Impact factor: 5.150

4.  The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong-A Territory-Wide Cohort Study.

Authors:  Jeffrey Sum-Lung Wong; Yawen Dong; Vikki Tang; Thomas Leung; Cynthia S Y Yeung; Anna Tai; Ada Law; Tracy Shum; Gerry Gin-Wai Kwok; Bryan Cho-Wing Li; Roland Leung; Joanne Chiu; Ka-Wing Ma; Wong-Hoi She; Josephine Tsang; Tan-To Cheung; Thomas Yau
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

5.  Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.

Authors:  R Wang; L D Ferrell; S Faouzi; J J Maher; J M Bishop
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

Review 6.  Biomarker development in MET-targeted therapy.

Authors:  Yanni Zhang; Zhiqiang Du; Mingqiang Zhang
Journal:  Oncotarget       Date:  2016-06-14

7.  [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology].

Authors:  M A Kern; K Breuhahn; M Schuchmann; P Schirmacher
Journal:  Pathologe       Date:  2007-07       Impact factor: 0.973

8.  Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.

Authors:  Zeynep Firtina Karagonlar; Dogukan Koc; Evin Iscan; Esra Erdal; Neşe Atabey
Journal:  Cancer Sci       Date:  2016-02-23       Impact factor: 6.716

Review 9.  Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Authors:  Mohamed Bouattour; Eric Raymond; Shukui Qin; Ann-Lii Cheng; Uz Stammberger; Giuseppe Locatelli; Sandrine Faivre
Journal:  Hepatology       Date:  2018-02-01       Impact factor: 17.425

10.  Interventional Potential of Recombinant Feline Hepatocyte Growth Factor in a Mouse Model of Non-alcoholic Steatohepatitis.

Authors:  Yoon Mee Yang; Masato Fukui; Zhijun Wang; Fiona Miao; Margo J Karriker; Ekihiro Seki
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-23       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.